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Abstract 
Purpose: To prepare hydrogels loaded with epicatechin, a strong antioxidant, anti-inflammatory, and 
neuroprotective tea flavonoid, and characterise them in situ as a vehicle for prolonged and safer drug 
delivery in patients with post-traumatic spinal cord injury.   
Methods: Five in situ gel formulations were prepared using chitosan and evaluated in terms of their 
visual appearance, clarity, pH, viscosity, and in vitro drug release. In vivo anti-inflammatory activity was 
determined and compared with 2 % piroxicam gel as standard. Motor function activity in a rat model of 
spinal injury was examined comparatively with i.v. methylprednisolone as standard.  
Results: The N-methyl pyrrolidone solution (containing 1 % w/w epicatechin with 2 to 10 % w/w 
chitosan) of the in situ gel formulation had a uniform pH in the range of 4.01 ± 0.12 to 4.27 ± 0.02. High 
and uniform drug loading, ranging from 94.48 ± 1.28 to 98.08 ± 1.24 %, and good in vitro drug release 
(79.48 ± 2.84 to 96.48 ± 1.02 % after 7 days) were achieved. The in situ gel prepared from 1 % 
epicatechin and 2 % chitosan (E5) showed the greatest in vivo anti-inflammatory activity (60.58 % 
inhibition of paw oedema in standard carrageenan-induced hind rat paw oedema model, compared with 
48.08 % for the standard). The gels showed significant therapeutic effectiveness against post-trauma-
induced spinal injury in rats. E5 elicited maximum motor activity (horizontal bar test) in the spinal injury 
rat model; the rats that received E5 treatment produced an activity score of 3.62 ± 0.02 at the end of 7 
days, compared with 5.0 ± 0.20 following treatment with the standard.  
Conclusion: In situ epicatechin-loaded gel exhibits significant neuroprotective and anti-inflammatory 
effects, and therefore can potentially be used for prolonged and safe drug delivery in patients with 
traumatic spinal cord injury. 
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Flavonoids are the largest group of bioactive 
polyphenols found in nature. Green and black 
teas are the richest sources of polyphenols, 
particularly flavanols and flavonols, which 
comprise 30 % of the dry weight of the fresh leaf. 
These dietary flavonoids and nutraceutical 
compounds—particularly epicatechin (EpC), 
catechin, and (−)-epigallocatechin-3-gallate 
(EGCG), which are the chief bioactive 
constituents—have a broad spectrum of activity. 
Green tea polyphenols, including EpC, reportedly 
exert antioxidant, anti-inflammatory, anti-
carcinogenic, antiviral, anti-arthritic, antibacterial, 
antiangiogenic, neuroprotective, and anti-
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hyperlipidemic effects. These flavones also 
induce apoptosis and cell cycle arrest in a wide 
array of cell lines, and protect against cerebral 
ischaemia [1,2].  
 
Among the various polyphenols, EpC reportedly 
exhibits a wide range of biological activities, such 
as antioxidant, antibacterial, anti-carcinogenic, 
and anti-tumour effects [3,4]. The 
neuroprotective effects induced by EpC and 
other various green tea extracts include 
attenuated ischaemic brain injury and inhibition 
of excitotoxicity and are evidenced by improved 
cognitive performance and memory retention; 
these effects may be utilised in patients with 
spinal cord injury (SCI) [5–8]. Trauma-induced 
SCI is one of the most challenging conditions to 
treat. The primary tissue injury leads to a 
cascade of adverse events, such as inflammation 
and apoptosis, which result in neuropathic pain, 
inflammation, and reversible and/or irreversible 
damage to the nervous system, known as 
secondary injury [9–12].   
 
The present work aimed to develop in situ EpC-
loaded hydrogels for localised drug delivery to 
the SC with the advantages of a reduced 
frequency of dosage, prolonged drug release, 
and improved patient compliance for the 
management of SCI. The prepared gels were 
characterised in terms of their the 
physicochemical properties, in vitro drug release, 
in vivo anti-inflammatory activity, and in vivo 






EpC and chitosan (75 % deacylated, Ch) were 
obtained from Sigma–Aldrich, US. Other 
chemicals used were of analytical grade.  
 
Preparation of in situ gels loaded with EpC 
 
A total of five formulations of pH-responsive in 
situ gels loaded with EpC were prepared using 
chitosan (Table 1). 
 









E1 1 10 
E2 1 8 
E3 1 6 
E4 1 4 
E5 1 2 
* N-methyl-2-pyrrolidone (NMP) was used as the 
solvent 
 
The polymeric solutions were prepared in NMP. 
EpC was gently dispersed in the solution with 
continuous stirring at 200 rpm. The pH of the 
resulting solution was maintained at 4.0. The 
solution thus obtained was degassed, followed 
by membrane filtration sterilisation. The prepared 
sterile in situ gels were stored in a sterile area in 
a vacuum desiccator until further use. 
 
Physicochemical characterisation  
 
Clarity was determined by visual inspection 
against a black and white background. The 
viscosity of the in situ gelling solution in the 
presence or absence of simulated biological fluid 
(SBF) was determined using a Brookfield 
viscometer. The pH was determined using a 
digital pH meter. 
 
To determine the drug content of each 
formulation, each formulation (5 mL removed 
after vigorous shaking) was mixed with 100 mL 
of methanol and continuously stirred at 300 rpm 
for 1 h. The resulting solution was centrifuged at 
100 rpm for 10 min. The clear supernatant was 
then analysed spectrophotometrically to 
determine the drug content.   
 
In vitro drug release studies 
 
An in vitro drug release study was performed 
using the method reported by Che et al [13]. The 
formulations were first brought to a gelled state 
by mixing 5 mL of the each formulation with 15 
mL of phosphate buffer (pH 7.4). This pregelled 
formulation was stored in a vial containing 
phosphate buffer (20 mL, pH 7.4) on a shaking 
water bath (37 ± 1 oC; 50 oscillations per min). 
Samples (1 mL each) were removed at 
predetermined time intervals for 1 week; at each 
sampling time point an equal volume of 
prewarmed fresh buffer was replaced in the vial. 
The samples were analysed by ultraviolet (UV) 
spectrophotometry to determine the drug release 




Healthy male Wistar rats (150 – 220 g) were 
used in this study. The rats were kept in cages 
and housed under standard light and 
temperature conditions. They were allowed free 
access to drinking water and a standard diet. The 
animal study protocols were approved by the 
Animal Care and Use Committee of Nanchang 
University, Nanchang (approval no. 2015/02b-
13). The studies were carried out in compliance 
with Directive 2010/63/EU on the handling of 
animals used for scientific purposes [14]. 
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In vivo anti-inflammatory studies 
 
The in vivo anti-inflammatory activity of the 
formulations was evaluated using the standard 
carrageenan-induced rat hind paw oedema 
model. Rats were divided into 6 groups of 6 rats 
each. The control group (Group I) rats were 
untreated. For Groups II to V, the in situ gel 
formulations were injected (20 mg/kg body 
weight; intra venous) into the left hind paw of the 
rats. Group VI received the 2 % piroxicam gel 
(standard). Paw oedema was induced 30 min 
later by injecting 0.1 mL of a 1 % w/v aqueous 
suspension of carrageenan into the left paws of 
all rats. The hind paw volume was measured 
immediately (0 h) and at predetermined time 
intervals using a plethysmometer, and was 
expressed as percent oedema relative to the 
initial hind paw volume. The percent inhibition of 
oedema was considered to reflect the anti-
inflammatory activity. 
 
In vivo motor function activity 
 
The rats were divided into 7 groups (normal 
control, negative control, standard, and 4 test 
groups) of 6 rats each (total, 42 rats). An in vivo 
motor function activity study was performed as 
reported by Che et al [13]. With the exception of 
the animals in the normal control group, all 
animals were subjected to laminectomy (to 
induce acute spinal injury) after administration of 
thiopental sodium (40 mg/kg). Specifically, 
extradural 40 g force clip compression was 
performed for 20 s at around T6 (until motor 
nerve activity is lost). The control group was 
administered the blank (non-medicated) gel. The 
test group received the in situ gels (50 mg/kg 
body weight; intrathecally [i.t.]) at a shaved site 
closest to the injury. The standard group 
received intravenous (i.v.) methylprednisolone 
(30 mg/kg body weight) at 30 min post-injury to 
allow for drug release. This daily treatment was 
repeated for 1 week. At the end of 7 days, motor 
function activity was assessed using a horizontal 
bar experiment. The time spent by rats on the 
horizontal bar was determined, and scoring was 
performed as follows. Activity scores were 
assigned according to the time spent by each rat 
on the horizontal bar (1–5 s = 1; 6–10 s = 2; 11–
20 s = 3; 21–30 s = 4; >30 s = 5; if bar support 




The results are expressed as means ± standard 
deviation (SD). Statistical analysis was 
performed using Origin 9 software (USA) and 
Student’s t-tests. A value of p < 0.05 was 




The gelling capacity of the polymer with SBF was 
determined, and suitable ratios for maximum 




Addition of SBF to the in situ gelling solutions, 
which were colourless and clear when inspected 
visually, resulted in formation of a viscous gel 
mass. The in situ gel formulation solution showed 
a uniform pH in the range of 4.01 ± 0.12 to 4.27 ± 
0.02 (Table 2). 
 
The formulation showed high and uniform drug 
loading, ranging from 94.48 ± 1.28 to 98.08 ± 
1.24 %. The viscosity of the formulations was 
found to increase 5- to 7-fold (Table 2) after 
gelling. The formulations showed a shear-
thinning property (Table 2), as has been reported 
previously.  
 
In vitro drug release studies 
 
In vitro drug release studies were performed in 
phosphate buffer at pH 7.4 to simulate the pH of 
biological fluid. The formulations showed drug 
release proportions ranging from 79.48 ± 2.02 to 
96.48 ± 1.05 % after 7 days (Fig 1). 
 
    Table 2:  Physicochemical characterisation of in situ gels loaded with EpC 
 
















E1 4.01 ± 0.12 95.00 ± 2.09 5.02 27.08 
E2 4.12 ± 0.02 98.04 ± 1.46 4.84 26.07 
E3 4.24 ± 0.01 97.24 ± 2.22 3.80 23.05 
E4 4.26 ± 0.02 94.48 ± 1.28 3.02 21.04 
E5 4.27 ± 0.02 98.08 ± 1.24 2.99 19.84 
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Fig. 1: In vitro epicatechin (EpC) release from in situ gels in phosphate buffer, pH 7.4 (-●-E1; -□- E2; -∆- E3; -×- 
E4; and -*- E5) 
 
In vivo anti-inflammatory activity 
 
Inhibition of carrageenan-induced paw oedema 
was taken as evidence of anti-inflammatory 
activity (Table 3). 
 
Table 3: Anti-inflammatory activity of in situ gels 













an = 6; b% inhibition of paw oedema 12 h after 
carrageenan injection against the paw volume of the 
control group (1.04 ± 0.10 mL) ; cp < 0.05 vs. control 
 
The reduction in the initial volume of paw 
oedema over time due to the effect of the 
standard drug or test formulation was assessed. 
The percent inhibition of paw oedema ranged 
from 52.88 to 60.58%, compared with 48.08 % 
for the standard.  
 
In vivo motor function activity  
 
The motor nerve activity elicited by the 
formulations was assessed using a rat model of 
post-traumatic SCI. After treatment for 7 days, 
the activity scores of the rodents treated with the 
in situ gels were 3.56, 3.4, 3.5, 3.6, and 3.62 for 
E1, E2, E3, E4, and E5, respectively. E5 elicited 
the optimum motor nerve activity in rats with 
traumatic SCI (Fig 2). 
 
 
Fig 2: In vivo motor function activity elicited by in situ gels loaded with EpC in a rat model of spinal injury after 1 
week of treatment 
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Each year, several million people suffer from 
serious traumatic peripheral nerve injuries 
globally. If the damaged nerves cannot be 
restored, loss of muscle function, impaired 
sensation, and painful neuropathies can result. 
Acute steroids have been reported to be an 
effective first-line therapy in traumatic SCI; 
indeed, a high dose of methylprednisolone given 
immediately after traumatic SCI is an accepted 
standard treatment [15]. Despite several reports 
of the effectiveness of i.v. methylprednisolone in 
traumatic SCI-induced nerve damage, it cannot 
cross the blood–spinal cord barrier.  This results 
in the need for frequent administration of large 
doses of methylprednisolone. 
 
Biodegradable polymers in the form of scaffolds, 
implants, or hydrogels are safe and effective 
platforms for site-specific or targeted drug 
delivery [16–19]. Localised drug delivery via 
intrathecal injections of polymeric systems in the 
SC likely elicits results comparable to those of 
conventional parenteral steroid therapy, but with 
a lower dose and prolonged drug release 
[13,20,21]. Injectable in situ hydrogel implants 
have been investigated in terms of their 
neuroprotective effects against SCI. These 
polymeric solutions are injectable and are 
converted into a hydrogel (i.e., viscous matrix 
depot form) due to a change in temperature, pH, 
ion cross-linking, or solvent removal [22–24]. 
 
In the present study, we prepared chitosan-
based in situ hydrogel implants; hydrogel 
formation was triggered by a change in pH and 
solvent removal [25]. Immediately after contact 
with an aqueous environment, the NMP solvent 
diffuses out, resulting in polymer precipitation. 
This ultimately results in the formation of a 
porous polymer matrix, which slowly releases the 
drug into the biological microenvironment. High 
drug loading was observed with the in situ gels 
showed, a property desirable for drug delivery. 
The rheology of the prepared formulation was 
also satisfactory with the consistency in which it 
could be easily injected. The viscosity of the 
formulation was governed by the nature and 
amount of polymer present. In principle, the in 
situ gel should not alter the basic rheological 
properties of the biological fluid at the site of 
action. In this case, the formulation was delivered 
into the intrathecal fluid, which is crucial for 
neuroprotection. Further studies to assess the 
effect of the in situ formed hydrogel on the 
rheology of the intrathecal fluid are warranted. 
 
The formulation with low chitosan content had 
better release properties. Use of a higher 
polymer content might have resulted in the 
formation of a stiffer gel, which would act as a 
barrier to drug diffusion. The in situ gel 
formulation E5 showed the highest anti-
inflammatory activity, 60.58 % inhibition of paw 
oedema compared with 48.08 % for the 
standard. This might have been due to the lower 
polymer concentration, which facilitated drug 
release. However, the E1, E2, and E3 
formulations may function better over time, as 
these released the drug over a prolonged period 
of time. Moreover, all of the formulations had 
better results than those seen following treatment 
with the standard. 
 
The horizontal bar method is a practical and 
easy-to-use method of assessing motor nerve 
activity in rats with post-traumatic SCI. The 
activity score of the model rats following 
treatment with the formulations was 3.4 – 3.6, 
and that following treatment with the standard 
was 5.0. Therefore, the motor nerve activity was 
greater after treatment with the EpC-loaded in 





Biodegradable polymers can be used in in situ 
EpC-loaded gels for continuous, extended drug 
release for a round-the-clock management of 
pain and inflammation in patients with SCI. The 
gel prepared from EpC and chitosan at a 1:4 
ratio exhibited the greatest potential for 
prolonged post-traumatic therapy of SCI due to 
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